- Home
- PG vs GILD Comparison
PG vs GILD Comparison
Compare PG & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PG | GILD |
|---|---|---|
| Founded | 1837 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 369.9B | 187.5B |
| IPO Year | 2014 | 2000 |
Fundamental Metrics
Financial Performance| Metric | PG | GILD |
|---|---|---|
| Price | $155.52 | $145.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 18 |
| Target Price | ★ $170.86 | $143.50 |
| AVG Volume (30 Days) | ★ 9.2M | 6.3M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 2.75% | 2.28% |
| EPS Growth | 8.14 | ★ 1684.21 |
| EPS | 3.73 | ★ 6.78 |
| Revenue | ★ $84,284,000,000.00 | $24,689,000,000.00 |
| Revenue This Year | $5.81 | $4.68 |
| Revenue Next Year | $2.65 | $6.10 |
| P/E Ratio | $41.24 | ★ $21.23 |
| Revenue Growth | 0.29 | ★ 9.98 |
| 52 Week Low | $137.62 | $95.30 |
| 52 Week High | $175.99 | $157.29 |
Technical Indicators
Market Signals| Indicator | PG | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 50.89 |
| Support Level | $149.94 | $143.09 |
| Resistance Level | $156.93 | $157.29 |
| Average True Range (ATR) | 2.99 | 3.27 |
| MACD | -1.49 | -1.43 |
| Stochastic Oscillator | 24.18 | 24.02 |
Price Performance
Historical ComparisonAbout PG Procter & Gamble Company (The)
Since its founding in 1837, Procter & Gamble has become one of the world's largest consumer product manufacturers, with annual sales of nearly $85 billion. It operates with a lineup of leading brands, including more than 20 that generate north of $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. Sales outside its home turf represent just more than half of the firm's consolidated total.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).